| Biological Sciences | Lifetime | 576 | US 330 | 99.93 |
| Biological Sciences | 2021-2025 | 46 | US 8 | 99.96 |
| Immunology | Lifetime | 28 | US 16 | 99.95 |
| Epidemiology | Lifetime | 475 | US 241 | 99.40 |
| Genetics | Lifetime | 448 | US 241 | 98.95 |
| Infectious Diseases | Lifetime | 305 | US 159 | 98.90 |
| Immunology | 2021-2025 | 2 | US 1 | 99.93 |
| Genetics | 2021-2025 | 32 | US 10 | 99.43 |
| Infectious Diseases | 2021-2025 | 71 | US 22 | 98.95 |
| Epidemiology | 2021-2025 | 402 | US 133 | 96.63 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 2 | US 2 | 99.98 |
| Blood disorders and treatments | Lifetime | 3 | US 3 | 99.81 |
| Mycobacterium research and diagnosis | Lifetime | 21 | US 12 | 99.77 |
| Immune responses and vaccinations | Lifetime | 4 | US 1 | 99.63 |
| Immune Cell Function and Interaction | Lifetime | 99 | US 67 | 99.86 |
| interferon and immune responses | Lifetime | 32 | US 20 | 99.68 |
| Immune Response and Inflammation | Lifetime | 141 | US 72 | 99.60 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 168 | US 65 | 99.24 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 96 | US 47 | 99.26 |
| Tuberculosis Research and Epidemiology | Lifetime | 149 | US 54 | 99.33 |
| Cytomegalovirus and herpesvirus research | Lifetime | 162 | US 105 | 98.99 |
| Diabetes and associated disorders | Lifetime | 171 | US 85 | 99.09 |
| T-cell and B-cell Immunology | Lifetime | 284 | US 157 | 99.41 |
| Parvovirus B19 Infection Studies | Lifetime | 64 | US 34 | 98.91 |
| NF-κB Signaling Pathways | Lifetime | 110 | US 47 | 98.70 |
| COVID-19 Clinical Research Studies | Lifetime | 580 | US 142 | 97.87 |
| Whipple's Disease and Interleukins | Lifetime | 21 | US 10 | 97.27 |
| RNA regulation and disease | Lifetime | 373 | US 180 | 96.75 |
| Pediatric health and respiratory diseases | Lifetime | 607 | US 207 | 96.34 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 733 | US 306 | 96.60 |
| Genomics and Rare Diseases | Lifetime | 611 | US 294 | 95.70 |
| Congenital Ear and Nasal Anomalies | Lifetime | 784 | US 319 | 78.58 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 1 | US 1 | 99.96 |
| interferon and immune responses | 2021-2025 | 1 | US 1 | 99.81 |
| Immune Cell Function and Interaction | 2021-2025 | 15 | US 9 | 99.53 |
| Diabetes and associated disorders | 2021-2025 | 6 | US 3 | 99.59 |
| Immune responses and vaccinations | 2021-2025 | 3 | US 1 | 99.13 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 160 | US 63 | 99.24 |
| Blood disorders and treatments | 2021-2025 | 7 | US 1 | 98.82 |
| Viral Infections and Immunology Research | 2021-2025 | 35 | US 13 | 97.47 |
| RNA regulation and disease | 2021-2025 | 24 | US 9 | 96.15 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 20 | US 8 | 96.94 |
| COVID-19 Clinical Research Studies | 2021-2025 | 530 | US 131 | 97.63 |
| Parvovirus B19 Infection Studies | 2021-2025 | 21 | US 9 | 95.86 |
| T-cell and B-cell Immunology | 2021-2025 | 247 | US 106 | 93.33 |
| Mycobacterium research and diagnosis | 2021-2025 | 238 | US 66 | 92.98 |
| Herpesvirus Infections and Treatments | 2021-2025 | 256 | US 91 | 89.83 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 291 | US 116 | 88.67 |
| NF-κB Signaling Pathways | 2021-2025 | 49 | US 8 | 83.64 |
| Respiratory viral infections research | 2021-2025 | 896 | US 296 | 88.80 |
| Immune Response and Inflammation | 2021-2025 | 460 | US 108 | 83.32 |
| Phagocytosis and Immune Regulation | 2021-2025 | 367 | US 106 | 77.61 |
| Whipple's Disease and Interleukins | 2021-2025 | 16 | US 6 | 78.67 |
| Adrenal Hormones and Disorders | 2021-2025 | 380 | US 55 | 79.82 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 557 | US 135 | 75.97 |
| Viral-associated cancers and disorders | 2021-2025 | 997 | US 353 | 76.53 |
| Dermatological and COVID-19 studies | 2021-2025 | 731 | US 115 | 51.50 |
